Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25 - @mgfakih#Cancer #OncoDaily #MedEd #MedX #MedNews #Medicine #Oncology #ASCOGI25
#Cancer #OncoDaily #MedEd #MedX #MedNews #Medicine #Oncology #ASCOGI25